Gene therapy for Beta-Thalassemia: will the fix last?
NCT ID NCT06717932
First seen Feb 11, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This study checks the long-term safety and effectiveness of a treatment called CS-101 in 8 people with beta-thalassemia who already received it in an earlier study. Researchers will monitor serious side effects and see if patients can stay free from blood transfusions for at least 12 months. No new treatment is given in this follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
Conditions
Explore the condition pages connected to this study.